Haleon, long-term profit growth and shares on the London market

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-28, 08:36.

Haleon (GB00BMX86B70) is back in view after a company update on medium-term profit growth and a separate analyst call on the shares. MarketScreener reported the operating-profit target on 24 June, while JPMorgan kept a Sell rating on 24 June as well.

What the company said

MarketScreener said Haleon is forecasting high single-digit growth in operating profit over the medium term. That is the headline number from the company update published on 24 June, and it gives investors a fresh benchmark for the consumer-health group. MarketScreener’s report on the update

JPMorgan stays cautious

The analyst side is equally concrete. MarketScreener’s timeline for Haleon lists JPMorgan’s 24 June note with a confirmed Sell rating, and it also records Rothschild & Co Redburn’s 18 June move to Neutral. That keeps the debate centered on valuation and execution, not on a single trading session. MarketScreener’s analyst timeline

Oral care and pain relief

Haleon’s consumer-health portfolio includes brands such as Sensodyne, Panadol and Advil, which sit across oral care, pain relief and other everyday health categories. That mix matters because it ties the medium-term profit target to established mass-market products rather than a single launch cycle.

London listing details

The Haleon shares (GB00BMX86B70) trade on the London market in sterling. Price, market cap and a live timestamp were not securely verifiable from the available search set.

Disclaimer: This article is for information only and does not constitute investment advice.